Tau Imaging in Alzheimer’s Disease Diagnosis and Clinical Trials

Jared R. Brosch, Martin Farlow, Shannon L. Risacher, Liana G. Apostolova

Research output: Contribution to journalArticle

6 Citations (Scopus)

Abstract

In vivo imaging of the tau protein has the potential to aid in quantitative diagnosis of Alzheimer’s disease, corroborate or dispute the amyloid hypothesis, and demonstrate biomarker engagement in clinical drug trials. A host of tau positron emission tomography agents have been designed, validated, and tested in humans. Several agents have characteristics approaching the ideal imaging tracer with some limitations, primarily regarding off-target binding. Dozens of clinical trials evaluating imaging techniques and several pharmaceutical trials have begun to integrate tau imaging into their protocols.

Original languageEnglish (US)
Pages (from-to)1-7
Number of pages7
JournalNeurotherapeutics
DOIs
StateAccepted/In press - Nov 21 2016

Fingerprint

Alzheimer Disease
Clinical Trials
tau Proteins
Dissent and Disputes
Amyloid
Pharmaceutical Preparations
Positron-Emission Tomography
Biomarkers

Keywords

  • Alzheimer’s disease
  • Tau
  • Tau imaging

ASJC Scopus subject areas

  • Pharmacology
  • Clinical Neurology
  • Pharmacology (medical)

Cite this

Tau Imaging in Alzheimer’s Disease Diagnosis and Clinical Trials. / Brosch, Jared R.; Farlow, Martin; Risacher, Shannon L.; Apostolova, Liana G.

In: Neurotherapeutics, 21.11.2016, p. 1-7.

Research output: Contribution to journalArticle

Brosch, Jared R. ; Farlow, Martin ; Risacher, Shannon L. ; Apostolova, Liana G. / Tau Imaging in Alzheimer’s Disease Diagnosis and Clinical Trials. In: Neurotherapeutics. 2016 ; pp. 1-7.
@article{c55ee6b00eaa40cd929d3ed447b5178a,
title = "Tau Imaging in Alzheimer’s Disease Diagnosis and Clinical Trials",
abstract = "In vivo imaging of the tau protein has the potential to aid in quantitative diagnosis of Alzheimer’s disease, corroborate or dispute the amyloid hypothesis, and demonstrate biomarker engagement in clinical drug trials. A host of tau positron emission tomography agents have been designed, validated, and tested in humans. Several agents have characteristics approaching the ideal imaging tracer with some limitations, primarily regarding off-target binding. Dozens of clinical trials evaluating imaging techniques and several pharmaceutical trials have begun to integrate tau imaging into their protocols.",
keywords = "Alzheimer’s disease, Tau, Tau imaging",
author = "Brosch, {Jared R.} and Martin Farlow and Risacher, {Shannon L.} and Apostolova, {Liana G.}",
year = "2016",
month = "11",
day = "21",
doi = "10.1007/s13311-016-0490-y",
language = "English (US)",
pages = "1--7",
journal = "Neurotherapeutics",
issn = "1933-7213",
publisher = "Springer New York",

}

TY - JOUR

T1 - Tau Imaging in Alzheimer’s Disease Diagnosis and Clinical Trials

AU - Brosch, Jared R.

AU - Farlow, Martin

AU - Risacher, Shannon L.

AU - Apostolova, Liana G.

PY - 2016/11/21

Y1 - 2016/11/21

N2 - In vivo imaging of the tau protein has the potential to aid in quantitative diagnosis of Alzheimer’s disease, corroborate or dispute the amyloid hypothesis, and demonstrate biomarker engagement in clinical drug trials. A host of tau positron emission tomography agents have been designed, validated, and tested in humans. Several agents have characteristics approaching the ideal imaging tracer with some limitations, primarily regarding off-target binding. Dozens of clinical trials evaluating imaging techniques and several pharmaceutical trials have begun to integrate tau imaging into their protocols.

AB - In vivo imaging of the tau protein has the potential to aid in quantitative diagnosis of Alzheimer’s disease, corroborate or dispute the amyloid hypothesis, and demonstrate biomarker engagement in clinical drug trials. A host of tau positron emission tomography agents have been designed, validated, and tested in humans. Several agents have characteristics approaching the ideal imaging tracer with some limitations, primarily regarding off-target binding. Dozens of clinical trials evaluating imaging techniques and several pharmaceutical trials have begun to integrate tau imaging into their protocols.

KW - Alzheimer’s disease

KW - Tau

KW - Tau imaging

UR - http://www.scopus.com/inward/record.url?scp=84996538780&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84996538780&partnerID=8YFLogxK

U2 - 10.1007/s13311-016-0490-y

DO - 10.1007/s13311-016-0490-y

M3 - Article

SP - 1

EP - 7

JO - Neurotherapeutics

JF - Neurotherapeutics

SN - 1933-7213

ER -